

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 October 2020 (01.10.2020)



(10) International Publication Number
WO 2020/198537 A1

(51) International Patent Classification:

A61K 31/192 (2006.01) A61P 37/02 (2006.01)
A61K 45/06 (2006.01) C07C 15/12 (2006.01)
A61P 17/04 (2006.01) C07D 213/00 (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2020/025077

(22) International Filing Date:

26 March 2020 (26.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/825,741	28 March 2019 (28.03.2019)	US
62/849,095	16 May 2019 (16.05.2019)	US
62/864,306	20 June 2019 (20.06.2019)	US
62/938,277	20 November 2019 (20.11.2019)	US
62/955,967	31 December 2019 (31.12.2019)	US
62/959,799	10 January 2020 (10.01.2020)	US

(71) Applicant: **ESCIENT PHARMACEUTICALS, INC.**

[US/US]; 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US).

(72) Inventors: **YEAGER, Adam**; 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **SELFRIDGE, Brandon**; 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **SAINZ, Marcos**; 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **MARTINBOROUGH, Esther**; 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **BOEHM, Marcus**; 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **HUANG, Liming**; 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US).

(74) Agent: **HERMANN, Karl, R.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS





FIG. 1



(57) Abstract: Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n , x , A , Q_1 , Q_2 , Z , R , R^1 , R^2 , R^3 , R^4 and R^5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

[Continued on next page]

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))